Phase II study of oral platinum drug JM216 as first-line treatment in patients with small-cell lung cancer.
about
Satraplatin: leading the new generation of oral platinum agentsThe new platinum-based anticancer agent LA-12 induces retinol binding protein 4 in vivoPhase 1 trial and pharmacokinetic study of the oral platinum analog satraplatin in children and young adults with refractory solid tumors including brain tumors.New-generation platinum drugs in the treatment of cisplatin-resistant cancers.An open-label, dose-finding study of the combination of satraplatin and gemcitabine in patients with advanced solid tumors.A phase 1/1b study of satraplatin (JM-216) in combination with docetaxel in patients with advanced solid tumors and metastatic castrate-resistant prostate cancerSatraplatin: an orally available platinum analog for the treatment of cancer.Broadening the clinical use of platinum drug-based chemotherapy with new analogues. Satraplatin and picoplatin.Satraplatin in the treatment of hormone-refractory metastatic prostate cancerNew-generation platinum agents for solid tumors.Satraplatin for the therapy of castration-resistant prostate cancer.Clinical and pharmacokinetic evaluation of satraplatin.Advances in oral delivery of anti-cancer prodrugs.Platinum-(IV)-derivative satraplatin induced G2/M cell cycle perturbation via p53-p21(waf1/cip1)-independent pathway in human colorectal cancer cells.The new platinum(IV) derivative LA-12 shows stronger inhibitory effect on Hsp90 function compared to cisplatin.
P2860
Q28972468-D24D938A-3245-4158-B221-FC5CC9C7DF5BQ34062814-07A9D4CA-3CFA-4191-9B43-DFDB39A7F3E1Q35118358-E2FBFDAF-94F7-4AD5-B66A-D720B32E0A9FQ36210926-1880003F-004F-4BFC-923B-F6DD9A626B70Q36417757-DFA2C8AF-5622-4936-81B8-281B679081D9Q36428631-991B7D0A-A664-456B-8B2D-34B8BE0EB0B4Q36532071-E8729C68-8A41-46BA-8271-089400324B7BQ36861592-4E2F0247-0D44-42B2-8193-C230D6C13741Q37160386-1CDE55D4-A76D-4C13-9208-39756D6D1E82Q37401326-58DC43FC-AF34-4434-A8A8-121E7F6E0626Q37605845-38A51D7E-4CAB-4C75-87FA-5D8337395CEEQ37958009-03C67CBA-F80F-4264-A87B-2256410C9EF9Q38862820-E0562FCA-32FB-4B09-A8D7-6894E1FB3693Q39018004-086A412D-054D-4860-8BDE-DDF238C4B86CQ39692780-D8CB5666-8969-4280-9214-D4220DCC2B00
P2860
Phase II study of oral platinum drug JM216 as first-line treatment in patients with small-cell lung cancer.
description
1999 nî lūn-bûn
@nan
1999 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Phase II study of oral platinu ...... s with small-cell lung cancer.
@ast
Phase II study of oral platinu ...... s with small-cell lung cancer.
@en
Phase II study of oral platinu ...... s with small-cell lung cancer.
@nl
type
label
Phase II study of oral platinu ...... s with small-cell lung cancer.
@ast
Phase II study of oral platinu ...... s with small-cell lung cancer.
@en
Phase II study of oral platinu ...... s with small-cell lung cancer.
@nl
prefLabel
Phase II study of oral platinu ...... s with small-cell lung cancer.
@ast
Phase II study of oral platinu ...... s with small-cell lung cancer.
@en
Phase II study of oral platinu ...... s with small-cell lung cancer.
@nl
P2093
P1476
Phase II study of oral platinu ...... s with small-cell lung cancer.
@en
P2093
P304
P356
10.1200/JCO.1999.17.12.3822
P407
P577
1999-12-01T00:00:00Z